CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
CRISPR Therapeutics AGNASDAQ: CRSP
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $4.24M fell 4.4% year over year, behind the -0.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.
Context
- Depreciation & amortization amounted to 555.0% of revenue in FY2025, up 499.9 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -4.4% toward the trailing-twelve-month pace of -0.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 19.48M USD
- Year-over-year change
- +1.1%
- 4-year CAGR
- +2.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.48M | +1.1% |
| FY2024 | 2024-12-31 | 19.26M | -2.9% |
| FY2023 | 2023-12-31 | 19.84M | -17.9% |
| FY2022 | 2022-12-31 | 24.17M | +34.6% |
| FY2021 | 2021-12-31 | 17.95M | — |
Depreciation & Amortization vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's LTM Sep 2026 depreciation & amortization of $18.5M is the 3rd largest of the 7 companies compared; the peer median is $12.75M.
- Its year-over-year change of -0.9% is the 2nd highest of 7, against a peer median of -8.4%.
- Depreciation & amortization amounts to 73.5% of revenue for CRSP, versus a peer median of 14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $56.42M | -13.9% | +11.5% | 39.9% | |
| LTM Jun 2026 | $22.24M | +1.2% | +16.4% | 14.3% | |
| LTM Sep 2026 | $18.5M | -0.9% | -6.9% | 73.5% | |
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $4.17M | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| Peer median (excluding CRSP) | $12.75M | -8.4% | +8.6% | 14.7% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 377.66M | (650.18M) | (153.61M) | (366.25M) | (581.6M) |
| Depreciation & Amortization | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 102.39M | 97.95M | 81.03M | 86.57M | 72.5M |
| Change in Working Capital | 26.86M | 19.85M | (193.59M) | 156.27M | 71.88M |
| Accounts Receivables | (161K) | 305K | (200M) | 175M | 25M |
| Inventory | (37.51M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 37.51M | 5.16M | (20.25M) | 0 | 44.89M |
| Other Working Capital | 27.02M | 14.38M | 26.66M | (18.73M) | 1.99M |
| Other Non-Cash Items | 14.11M | 12.47M | (14.05M) | (38.62M) | 72.73M |
| Operating Cash Flow | 538.97M | (495.74M) | (260.38M) | (142.77M) | (345.01M) |
| Capital Expenditures | (81.71M) | (37.19M) | (9.47M) | (1.9M) | (914K) |
| Acquisitions (Net) | 953.73M | 221.47M | 0 | 0 | 0 |
| Purchases of Investments | (1.51B) | (1.42B) | (1.07B) | (1.49B) | (1.01B) |
| Sales of Investments | 555.6M | 1.2B | 1.45B | 1.21B | 1.01B |
| Other Investing Activities | (953.73M) | (221.47M) | (2.5M) | 0 | (34M) |
| Investing Cash Flow | (1.04B) | (258.66M) | 374.65M | (280.48M) | (31.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 213.27M | 970K | 62.66M | 300.7M | 426.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.68M | 37.62M | 0 | 31.29M | 0 |
| Financing Cash Flow | 250.95M | 38.59M | 62.66M | 331.98M | 426.03M |
| Effect of Forex Changes | (11K) | (80K) | 656K | (21K) | 95K |
| Net Change in Cash | (245.52M) | (715.88M) | 177.59M | (91.29M) | 49.3M |
| Free Cash Flow | 457.27M | (532.93M) | (269.85M) | (144.68M) | (345.93M) |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.